An Open-Label Study to Investigate the Pharmacokinetics of MK-5172 and MK-8742 in Subjects With Renal Insufficiency
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2019
Price : $35 *
At a glance
- Drugs Elbasvir (Primary) ; Grazoprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 25 Jan 2019 Population pharmacokinetic analyses results from NCT01937975 and NCT02092350 trial published in the European Journal of Clinical Pharmacology
- 28 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 22 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.